Siglec and anti-Siglec therapies. (June 2021)

• Record Type: Journal Article
• Authors: Murugesan, Gavuthami; Weigle, Bernd; Crocker, Paul R.
• Is Part Of: Current opinion in chemical biology. Volume 62(2021)
• Page Start: 34
• Page End: 42
• Publication Date: 2021-06
• Subjects: Siglec -- Sialic acid -- Cancer -- Inflammation -- Immune checkpoint; Ab antibody -- ADCC antibody-dependent cellular cytotoxicity -- CAR chimeric antigen receptor -- CMAS CMP-N-acetylneuraminate synthetase -- COPD chronic obstructive pulmonary disease -- DAP-10 DNAX-activating protein-10 -- DAP-12 DNAX-activating protein-12 -- GNE UDP-GlcNAc-2-epimerase -- ITIM immunoreceptor tyrosine-based inhibitory motif -- mAb monoclonal antibody -- NK natural killer -- SAM sialic acid mimetic -- Siglec sialic acid–binding Ig-like lectin -- SLE systemic lupus erythematosus -- ST sialyltransferase -- STAL Siglec-tolerizing antigenic liposome -- TAM tumour-associated macrophage -- Treg regulatory T cells; Bioorganic chemistry -- Periodicals; Biology -- Periodicals; Biochemistry -- Periodicals; Clinical biochemistry -- Periodicals; Biochemistry -- Periodicals; Chimie bio-organique -- Périodiques; Biologie -- Périodiques; 572.05
• DOI: 10.1016/j.cbpa.2021.01.001
• Languages: English
• ISSNs: 1367-5931

Abstract

Abstract: Siglecs (sialic acid–binding immunoglobulin-like lectins) are a family of receptors that bind sialic acids in specific linkages on glycoproteins and glycolipids. Siglecs play roles in immune signalling and exhibit cell-type specific expression and endocytic properties. Recent studies suggest that Siglecs are likely to function as immune checkpoints that regulate responses in cancers and inflammatory diseases. In this review, we discuss strategies to target the Siglec–sialic acid axis in human diseases, particularly cancer, and the possibility of exploiting them for therapeutic intervention. Graphical abstract: Image 1